A61L12/12

EYE WASH COMPOSITIONS AND METHODS
20230030714 · 2023-02-02 ·

This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

EYE WASH COMPOSITIONS AND METHODS
20230030714 · 2023-02-02 ·

This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

Ophthalmic device packaging solutions comprising tris(hydroxymethyl)aminomethane and nonionic surfactant

A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9.

Ophthalmic device packaging solutions comprising tris(hydroxymethyl)aminomethane and nonionic surfactant

A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9.

Contact Lens Cleaning Systems
20170348738 · 2017-12-07 ·

A cleaning system configured to use a hydrogen peroxide solution to clean contact lenses. The cleaning system includes a reservoir to hold the cleaning solution and a complex base coupled to the reservoir to insure a hermetically closed reservoir environment. The complex base is separated into at least a first and a second segment. A lens holder assembly holds the lenses within the solution and is coupled to the complex base in the first segment. A motor is located in the second segment of the complex base to selectively introduce a catalyst to the cleaning solution. The cleaning system has additional features that permit the system to allow for the storage of the contact lenses by converting a neutralized cleaning solution into a storage solution to prevent recontamination.

Contact lens disinfecting system
09833536 · 2017-12-05 · ·

A contact lens storage system that includes sterilized solution, at least one contract lens, a buffering agent, and a container. The sterilized solution and contact lens are physically separated from the buffering agent. Also described herein are related methods for neutralizing a sterilized contact lens solution, methods of inserting a contact lens onto an eye, and methods of disinfecting and neutralizing a contact lens.

Ophthalmic device packaging solutions comprising a poloxamine/erythritol mixture

A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9.

Ophthalmic device packaging solutions comprising a poloxamine/erythritol mixture

A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9.

Method for Disinfecting Contact Lenses
20170252478 · 2017-09-07 ·

A method for disinfecting contact lenses, including immersing the contact lenses in a volume of cleaning agent with about 3% hydrogen peroxide for up to 4 hrs, and immersing up to 0.7 g of a fibrous catalyst enhancer material in the volume of cleaning agent for up to 4 hrs. The fibrous catalyst enhancer material is immersed simultaneously with the contact lenses.

MULTILAYER DRUG DELIVERY COATING FOR CONTACT LENS

Ophthalmic devices coated with an active agent eluting coating are provided herein. Placement of the coated ophthalmic devices on the surface of eye results in modulation of cells responding to an immune modifying agent and reducing inflammation-related complications in the eye. Methods for treating ocular disorders are also provided herein. The disclosed subject matter is based, in part, on the discovery that ophthalmic devices coated with a cytokine eluting coating can shift early-stage macrophage polarization associated with alleviation of symptoms and causes of inflammatory ocular disorders.